Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccines

Cancer Gene Therapy

Volumn 18, Issue 8, 2011, Pages 563-570

  Lebson, L ^a   Wang, T ^b   Jiang, Q ^c   Whartenby, K A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c QIAGEN   (United States)

Author keywords

dendritic cell; dendritic cell vaccine; GILZ; immunotherapy; tumor vaccine

Indexed keywords

CD86 ANTIGEN; DENDRITIC CELL VACCINE; GLUCOCORTICOID INDUCED LEUCINE ZIPPER PROTEIN; LEUCINE ZIPPER PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TUMOR MICROENVIRONMENT;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DEXAMETHASONE; DOWN-REGULATION; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; LEUCINE ZIPPERS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 79960562293     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.23     Document Type: Article

References (36)

1. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68: 5955-5964.
2. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al. Vaccination of malignant glioma patients with peptidepulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842-847. (Pubitemid 32175145)
3. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 4160-4167. (Pubitemid 40791581)
4. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008; 15: 114-121. (Pubitemid 50017630)
5. Mule JJ. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci 2009; 1174: 33-40.
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332. (Pubitemid 28144092)
7. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002; 51: 669-673. (Pubitemid 35446294)
8. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-\{alpha\}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15: 4986-4992.
9. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008; 20: 1305-1311.
10. Lehrfeld TJ, Lee DI. Dendritic cell vaccines for the treatment of prostate cancer. Urol Oncol 2008; 26: 576-580.
11. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49: 124-132.
12. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22: 1007-1017. (Pubitemid 351689883)
13. Palma M, Adamson L, Hansson L, Kokhaei P, Rezvany R, Mellstedt H et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother 2008; 57: 1705-1710.
14. Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40: 108-116. (Pubitemid 351363421)
15. Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother 2004; 53: 777-785. (Pubitemid 39149904)
16. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009; 11: 653-668.
17. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383.
18. Kim SO, Ono K, Tobias PS, Han J. Orphan nuclear receptor Nur77 is involved in caspase-independent macrophage cell death. J Exp Med 2003; 197: 1441-1452. (Pubitemid 36682543)
19. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970-2976. (Pubitemid 37093519)
20. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65: 309-316. (Pubitemid 40070823)
21. Wang T, Jiang Q, Chan C, Gorski KS, McCadden E, Kardian D et al. Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. Blood 2009; 113: 2906-2913.
22. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med 2009; 41: 61-66.
23. Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004; 11: 165-173. (Pubitemid 38280519)
24. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-812. (Pubitemid 28064893)
25. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. Faseb J 2009; 23: 3649-3658.
26. Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem 1992; 267: 10219-10224.
27. Schoenenberger GA, Cueni LB, Monnier M, Hatt AM. Humoral transmission of sleep. VII. Isolation and physicalchemical characterization of the 'sleep inducing factor delta'. Pflugers Arch 1972; 338: 1-17.
28. Asselin-Labat ML, Biola-Vidamment A, Kerbrat S, Lombes M, Bertoglio J, Pallardy M. FoxO3 mediates antagonistic effects of glucocorticoids and interleukin-2 on glucocorticoid-induced leucine zipper expression. Mol Endocrinol 2005; 19: 1752-1764. (Pubitemid 41007888)
29. Cannarile L, Cuzzocrea S, Santucci L, Agostini M, Mazzon E, Esposito E et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology 2009; 136: 530-541.
30. Cohen N, Mouly E, Hamdi H, Maillot MC, Pallardy M, Godot V et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 2006; 107: 2037-2044. (Pubitemid 43289388)
31. Hamdi H, Bigorgne A, Naveau S, Balian A, Bouchet-Delbos L, Cassard-Doulcier AM et al. Glucocorticoid-induced leucine zipper: a key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis. Hepatology 2007; 46: 1986-1992.
32. Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet-Delbos L et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003; 101: 729-738. (Pubitemid 36077600)
33. Godot V, Garcia G, Capel F, Arock M, Durand-Gasselin I, Asselin-Labat ML et al. Dexamethasone and IL-10 stimulate glucocorticoid-induced leucine zipper synthesis by human mast cells. Allergy 2006; 61: 886-890. (Pubitemid 43893992)
34. Whartenby KA, Straley EE, Kim H, Racke F, Tanavde V, Gorski KS et al. Transduction of donor hematopoietic stemprogenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002; 100: 3147-3154. (Pubitemid 35217062)
35. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009; 20: 1106-1118.
36. Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108: 177-188. (Pubitemid 36232867)